

## **Apathy and Its Response to Antipsychotic Review and Nonpharmacological Interventions in People With Dementia Living in Nursing Homes**

Rajkumar, Anto; Ballard, Clive ; Fossey, Jane; Corbett, Anne; Woods, Robert; Orrell, Martin; Prakash, Rohan; Moniz-Cook, Esme; Testad, Ingelin

**Journal of the American Medical Directors Association**

DOI:

[10.1016/j.jamda.2016.04.006](https://doi.org/10.1016/j.jamda.2016.04.006)

Published: 01/08/2016

Version created as part of publication process; publisher's layout; not normally made publicly available

[Cyswllt i'r cyhoeddiad / Link to publication](#)

*Dyfyniad o'r fersiwn a gyhoeddwyd / Citation for published version (APA):*

Rajkumar, A., Ballard, C., Fossey, J., Corbett, A., Woods, R., Orrell, M., Prakash, R., Moniz-Cook, E., & Testad, I. (2016). Apathy and Its Response to Antipsychotic Review and Nonpharmacological Interventions in People With Dementia Living in Nursing Homes: WHELD, a Factorial Cluster Randomized Controlled Trial. *Journal of the American Medical Directors Association*, 17(8), 741-747. <https://doi.org/10.1016/j.jamda.2016.04.006>

### **Hawliau Cyffredinol / General rights**

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal ?

### **Take down policy**

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.



JAMDA

journal homepage: [www.jamda.com](http://www.jamda.com)

## Original Study

# Apathy and Its Response to Antipsychotic Review and Nonpharmacological Interventions in People With Dementia Living in Nursing Homes: WHELD, a Factorial Cluster Randomized Controlled Trial

Anto P. Rajkumar MD, PhD <sup>a,b,c,\*</sup>, Clive Ballard MD <sup>a,b</sup>, Jane Fossey DPsych <sup>d</sup>, Anne Corbett PhD <sup>a</sup>, Bob Woods FBPSS <sup>e</sup>, Martin Orrell FRCPsych <sup>f</sup>, Rohan Prakash <sup>g</sup>, Esme Moniz-Cook PhD <sup>h</sup>, Ingelin Testad PhD <sup>a</sup>

<sup>a</sup> Department of Old Age Psychiatry, Institute of Psychiatry, Psychology, and Neuroscience, King's College London, London, UK

<sup>b</sup> Mental Health of Older Adults and Dementia Clinical Academic Group, South London and Maudsley NHS Foundation Trust, London, UK

<sup>c</sup> Initiative for Integrative Psychiatric Research, iPSYCH, Aarhus, Denmark

<sup>d</sup> Oxford Health NHS Foundation Trust, Oxford, UK

<sup>e</sup> North Wales Organisation for Randomised Trials in Health, Bangor University, Bangor, UK

<sup>f</sup> Institute of Mental Health, University of Nottingham, Nottingham, UK

<sup>g</sup> University College London, London, UK

<sup>h</sup> Faculty of Health and Social Sciences, University of Hull, Hull, UK

## A B S T R A C T

**Keywords:**  
Apathy  
dementia  
randomized controlled trial

**Objectives:** Apathy is common, impactful, and difficult to manage in people with dementia. We evaluated the efficacy of nonpharmacological interventions, exercise, and social interaction, in combination with antipsychotic review, to reduce apathy in people with dementia living in nursing homes in a cluster randomized controlled trial (RCT).

**Methods:** Well-being and health for people with dementia (WHELD) program included a  $2 \times 2 \times 2$  factorial cluster RCT involving people with dementia living in 16 nursing homes in the United Kingdom. All homes received training in person-centered care, and were randomized to receive antipsychotic review, social interaction, and exercise, either alone or in combinations. Apathy was one of the secondary outcomes of the WHELD trial, and it was measured by the Neuropsychiatric Inventory–nursing home version at baseline and 9 months ( $n = 273$ ). We used multilevel mixed effects linear regression models to assess the impact of the interventions on apathy.

**Results:** Prevalence of apathy was 44.0% ( $n = 120$ ; 95% confidence interval [CI] 38.1%–49.9%) at baseline. Severity of apathy had significant positive correlations with dementia severity, neuropsychiatric symptoms, depressive symptoms, agitation, and the needs of the people with dementia ( $P < .001$ ). Antipsychotic review reduced antipsychotic use, but it significantly increased apathy ( $\beta = 5.37$ ; SE = 0.91;  $P < .001$ ). However, antipsychotic review in combination with either social interaction ( $\beta = -5.84$ ; SE = 1.15;  $P < .001$ ) or exercise ( $\beta = -7.54$ ; SE = 0.93;  $P < .001$ ) significantly reduced apathy.

**Conclusions:** Antipsychotic review can play a significant role in improving apathy in people with dementia living in nursing homes, when combined with psychosocial interventions such as social interaction and exercise. Guidance must be adapted to reflect this subtlety in care.

© 2016 AMDA – The Society for Post-Acute and Long-Term Care Medicine.

The authors declare no conflicts of interest.

The WHELD study was funded by the National Institute for Health Research (NIHR) program grants for applied research program (RP-PG-0608–10133). The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health.

\* Address correspondence to Anto Praveen Rajkumar, MD, DNB, MRCPsych, PhD, Department of Old Age Psychiatry, Institute of Psychiatry, Psychology, and Neuroscience, King's College London, 16, De Crespigny Park, London SE5 8AF, United Kingdom.

E-mail address: [Anto.Rajamani@kcl.ac.uk](mailto:Anto.Rajamani@kcl.ac.uk) (A.P. Rajkumar).

<http://dx.doi.org/10.1016/j.jamda.2016.04.006>

1525–8610/© 2016 AMDA – The Society for Post-Acute and Long-Term Care Medicine.

Dementia affects 35 million people around the world. As the condition progresses, many individuals move to reside in long-term care facilities. In the United Kingdom, these people account for one-third of people with dementia,<sup>1</sup> whereas 64% of people receiving Medicare in US nursing homes have dementia.<sup>2</sup> These individuals have complex needs due to the unique set of cognitive and functional impairments that characterize moderate to severe dementia. These are further compounded by neuropsychiatric symptoms, medical comorbidity,

and loss of communication ability.<sup>3</sup> Neuropsychiatric symptoms affect 90% of people with dementia at some point, and are particularly impactful with individuals requiring additional support to initiate and engage with activities.<sup>4</sup> Apathy is possibly the most frequent neuropsychiatric symptom, but is relatively underresearched.

Apathy is not merely a symptom, but a multidimensional syndrome affecting cognitive, emotional, and behavioral domains,<sup>5,6</sup> and it causes clinically significant functional impairment in many people with dementia.<sup>7</sup> It is widely prevalent, persistent, and therapeutically challenging in people with dementia,<sup>8</sup> especially those with moderate to severe dementia living in nursing homes.<sup>9</sup> A recent systematic review including 28 studies reported the mean prevalence of apathy in people with dementia living in nursing homes to be 36% (range: 17%–82%).<sup>9</sup> Moreover, apathy is associated with high levels of disability, faster cognitive and functional decline, weight loss, poor quality of life, high caregiver burden, poor quality of care, poor rehabilitation, and increased risk of mortality.<sup>8,10–13</sup>

Systematic research on the management of apathy remains sparse.<sup>10,14</sup> Acetylcholinesterase inhibitors have level II evidence to support their efficacy.<sup>14</sup> In the context of an increasing effort to reduce the use of antipsychotic medications in people with dementia, available evidence does not support the use of antipsychotics to treat apathy.<sup>14–16</sup> The literature regarding nonpharmacological treatments for apathy is limited,<sup>10</sup> but some preliminary studies indicate the potential of tailored therapeutic mentally stimulating activities,<sup>17</sup> exercise,<sup>18</sup> and social interaction.<sup>19</sup>

As a part of a cluster randomized controlled trial (RCT) focusing on people with dementia in nursing homes, we examined the impact of a pragmatic intervention to review antipsychotic medication. The initial results confirmed that this intervention could achieve a significant reduction in antipsychotic use, and that in combination with social interaction there was also a significant reduction in mortality. There was, however, a significant worsening in agitation and overall psychiatric symptoms, which was mitigated by social interaction and/or exercise.<sup>20</sup> This article examined the frequency of apathy, determined whether review of antipsychotic medication led to any worsening of apathy, and whether this could be mitigated by evidence-based nonpharmacological interventions.

## Material and Methods

### Study Design

The Well-being and Health for people with Dementia (WHELD) program included this cluster RCT with  $2 \times 2 \times 2$  factorial design with 2 replications.<sup>21</sup> As the methodology used in this study has been reported in detail elsewhere,<sup>20</sup> it is only briefly presented here. The unit of randomization was the nursing home. Each nursing home (cluster) received a randomly allocated intervention, with most homes randomly assigned to more than 1 of the 3 interventions, for 9 months. The study received ethical approval from South-Central Oxford Research Ethics Committee C (REC number 11/SC0066). The trial is registered as a clinical trial (ISRCTN number 40313497), and the protocol is available online at <http://www.kcl.ac.uk/ioppn/depts/wolfson/about/people/staff/ballardclive.aspx>.

### Setting

This study was conducted in 16 nursing homes in the United Kingdom. Each care home represented a cluster that received a randomly allocated intervention for 9 months. These nursing homes were identified from those rated “adequate” or better in the care quality commission register in 2013, in the Oxfordshire, Buckinghamshire, and London localities. Eight homes were selected by probability sampling, and the remaining 8 were selected by

nonprobability sampling. We excluded the nursing homes if fewer than 60% of their residents had dementia or they were in receipt of local authority special support.

### Participants

All residents meeting eligibility criteria were invited to participate. Eligibility criteria included the diagnosis of dementia, defined by the Clinical Dementia Rating Scale (CDRS)<sup>22</sup> stage 1 or greater, and by Functional Assessment Staging (FAST)<sup>23</sup> stage 4 or greater. Consent for nursing home involvement was obtained from the management of the homes. If residents lacked capacity to consent, informed consent was obtained with the involvement of a nominated or personal consultee who represented the residents’ interests and wishes in accordance with the Mental Capacity Act. Study interventions were delivered to all residents, with a minimum recruitment target of 12 participants per nursing home. The impact of study interventions on antipsychotic use, agitation, depression, neuropsychiatric symptoms, and mortality of these participants have already been reported elsewhere.<sup>20</sup>

### Interventions

WHELD therapists worked with care staff nominated as dementia champions in each home to implement the following 4 interventions: (1) *Person-Centred Care* (PCC): PCC was implemented using the tools from the Focused Intervention for Training of Staff manual,<sup>24</sup> based on evidence-based approaches for improving care in nursing homes, and from a review of other best available training manuals with the aim of personalizing and tailoring care practice in line with individual preferences and needs.<sup>25</sup> (2) *Antipsychotic review*: The WHELD therapists helped the homes’ dementia champions to develop effective processes within the nursing homes to prompt antipsychotic review according to the best practice guidelines. Moreover, they worked with the physicians and nursing home staff to augment PCC during the antipsychotic withdrawal period. The participants’ primary care physicians or specialist psychiatrists reviewed long-term prescriptions of antipsychotics on the basis of the National Institute for Health and Care Excellence (NICE) dementia guidelines<sup>26</sup> and of the antipsychotic care pathway, developed by the Alzheimer’s Society in partnership with the Department of Health.<sup>27</sup> These guidelines emphasized careful medical assessment of underlying causes of neuropsychiatric symptoms, such as pain and factors leading to delirium, the use of nonpharmacological interventions as a first-line approach before considering pharmacotherapy (unless symptoms were severe or involving immediate risks), regular review of antipsychotic prescriptions in people on long-term antipsychotic medications, and the recommendation to constrain treatment periods with newly commenced antipsychotics to a maximum duration of 12 weeks. A trial discontinuation was recommended as the preferred practice for patients who had had antipsychotic prescriptions for more than 3 months, but caution was recommended in people with baseline Neuropsychiatric Inventory scores above 14 on the basis of evidence from a previous RCT.<sup>28</sup> (3) *Exercise*: Enjoyable positive physical activities were encouraged on the basis of the Seattle protocols<sup>29</sup> and exercise elements of the Needs Environment Stimulation Techniques (NEST) manual.<sup>30</sup> Previous and current interests of the participants, and their current level of health and fitness were assessed. The aim was for participants to be engaged in at least 1 hour of exercise per week. If they were doing this at baseline, the amount of exercise was increased by 20% by the end of the intervention period. (4) *Social interaction with pleasant activities*: A social interaction intervention manual was developed on the basis of three evidence-based approaches, the positive events schedule from the Seattle protocols,<sup>29</sup> the social activities elements of the NEST manual,<sup>30</sup> and the social interaction intervention, developed by Cohen-Mansfield and

colleagues.<sup>31</sup> Individualized plans for activities and staff-resident interactions were developed using a life history approach and assessment of current interests. The aim was for participants to be engaged in at least 1 hour of social interaction per week. If this was taking place at baseline, the amount of social interaction was increased by 20% by the end of the intervention period.

### Randomization

All 16 nursing homes received PCC. After constrained complete list randomization, stratified on the 3 participating sites,<sup>32</sup> antipsychotic review, exercise, and social interaction were implemented in 8 care homes each. The constraint ensured an approximately equal distribution of the number of study interventions to each geographic location. Eight nursing homes were randomly assigned to antipsychotic review, 8 to an intervention to increase social interaction, and 8 to an exercise intervention. Each possible combination of interventions was assigned to 2 nursing homes exclusively. A trained WHELD therapist coordinated each intervention into the 8 nursing homes that were randomized to receive that intervention. In each nursing home, a minimum of 2 lead care staff members were trained to implement that intervention.

### Outcome Measures

Apathy was one of the outcomes of the WHELD trial, and it was assessed by the Neuropsychiatric Inventory–Nursing Home version

(NPI-NH).<sup>33</sup> G domain of the NPI-NH evaluated apathy over the 4 weeks before assessment using a screening question, and 7 sub-questions. When apathy was identified, NPI-NH documented its frequency on a 4-point scale, and its severity on a 3-point scale. An apathy domain score was calculated by multiplying frequency and severity scores. This score was zero when apathy was absent, and it ranged from 1 to 12, when apathy was present. Depression, anxiety, and agitation of the participants were evaluated using the Cornell Scale for Depression in Dementia (CSDD),<sup>34</sup> Rating Anxiety In Dementia (RAID),<sup>35</sup> and Cohen-Mansfield Agitation Inventory (CMAI),<sup>36</sup> respectively. Needs and quality of life of the participants were systematically assessed using the Camberwell Assessment of Need for the Elderly (CANE)<sup>37</sup> and assessment of quality of life for people with dementia (DEMqoL),<sup>38</sup> respectively. Assessments were carried out at baseline before randomization, and after the completion of 9 month-long interventions by research assistants, blind to intervention allocation. The factorial design with all nursing homes receiving at least 1 intervention helped in maintaining the blinding.

### Statistical Analyses

We analyzed the data from the WHELD cluster RCT using data pertaining to apathy from the same randomized participants reported previously.<sup>20</sup> Participants' characteristics, their clinical profile, and apathy scores were initially analyzed by descriptive statistics. Missing values of items within the study questionnaires were replaced with the mean scores of the remaining items in the questionnaires as long




Fig. 1. CONSORT diagram showing flow of participants.

as the number of missing items did not exceed 20% of the total number of items in the questionnaires. Prevalence of apathy at baseline was compared with that after the 9-month intervention period using the McNemar test. Statistical significance of difference between the NPI-NH G domain apathy scores at the 2 time points was analyzed by the Wilcoxon signed-rank test. Appropriate statistical tests of significance were used to analyze the observed differences between the participants with and without apathy. Correlations between apathy scores and CDR, FAST, CSDD, RAID, CMAI, CANE, and DEMQoL scores were assessed using the Spearman rank-order correlation with Bonferroni corrections at baseline and after the 9-month intervention period.

The impact of antipsychotic review on apathy in people with dementia living in nursing homes was analyzed by multilevel mixed effects linear regression models with maximum likelihood estimation method. Further analyses were undertaken to determine the impact of combining antipsychotic review with social interaction or exercise. Individual participants were nested within a higher level, the nursing homes. Differences between the NPI-NH apathy scores at the 2 time points was the outcome variable. Study interventions were the independent variables. Age and gender of the participants, as well as FAST and CSDD scores at baseline were included as covariates. Although FAST stages were naturally ordered, they were modeled as linear effects to increase the power of the statistical analyses. Participants who did not receive any interventions except the PCC intervention formed the reference group. Clustered robust standard errors for the estimated regression coefficients were calculated with the nursing homes as the clustering variable. Only the participants who completed the 9-month intervention period were included in these analyses. We repeated these analyses by including only the participants with moderately severe and severe dementia, defined by FAST stages 6 and 7 at baseline. All analyses were performed using the statistical software STATA 13.1 (StataCorp, College Station, TX).

## Results

### Participant Characteristics

A total of 273 people with dementia living in 16 nursing homes were assessed for apathy at baseline, and 191 (70.0%) of them completed the 9-month intervention period. Figure 1 presents the participant flow diagram of the WHELD RCT. Presence of apathy at baseline was not significantly associated with death ( $\chi^2 = 0.10$ ;  $df = 1$ ;  $P = .75$ ), but was significantly associated with withdrawal from the study ( $\chi^2 = 8.04$ ;  $df = 1$ ;  $P = .005$ ). Table 1 presents the baseline characteristics of participants with and without apathy; 73.6% (95% confidence interval [CI] 68.0%–78.5%) of the participants were women, and 89.0% (95% CI 84.7%–92.2%) of them were Caucasian. Mean age of the participants was 85.3 (95% CI 84.4–86.1) years at baseline. Age of the participants did not differ significantly among the 16 nursing homes (Kruskal-Wallis  $\chi^2 = 16.18$ ;  $df = 15$ ;  $P = .37$ ). Table 2 presents baseline characteristics of the participants who received and did not receive antipsychotic review, social interaction, and exercise.

### Prevalence and Correlates of Apathy

A total of 120 participants (44.0%; 95% CI 38.1%–49.9%) had apathy at baseline. Mean NPI-NH G domain apathy scores at baseline was 2.32 (95% CI 1.91–2.73). Participants with and without apathy at baseline did not differ significantly in gender, age, ethnicity, number of years living in the nursing homes, or the current prescription of antipsychotic medications. Table 3 presents the correlations between NPI-NH apathy scores and severity of dementia, neuropsychiatric symptoms, depressive symptoms, anxiety symptoms, agitation,

**Table 1**

Baseline Characteristics of Participants With ( $n = 120$ ) and Without Apathy ( $n = 153$ )

Characteristic	Without Apathy, n (%) / Mean (SD)	With Apathy,* n (%) / Mean (SD)	$\chi^2/t/z^\dagger$	P
Female gender	113 (73.9)	88 (73.3)	0.01	.92
Age, y	85.7 (6.8)	84.7 (7.0)	1.13 <sup>‡</sup>	.26
Ethnicity: White	136 (88.9)	107 (89.2)	0.01	.94
Years lived in nursing homes	2.1 (2.0)	2.5 (2.2)	−1.21 <sup>‡</sup>	.22
CDR			25.34	<.001
Mild, 0.5–1	28 (18.3)	5 (4.2)		
Moderate, 2	72 (47.1)	40 (33.3)		
Severe, 3	53 (34.6)	75 (62.5)		
FAST			15.35	.002
Mild	25 (16.3)	5 (4.2)		
Moderate	12 (7.8)	4 (3.3)		
Moderately severe	94 (61.4)	82 (68.3)		
Severe	22 (14.4)	29 (24.2)		
NPI-NH total score <sup>§</sup>	9.7 (11.4)	25.5 (18.5)	−8.72 <sup>‡</sup>	<.001
CMAI total score	43.7 (15.0)	53.8 (17.5)	−5.07 <sup>‡</sup>	<.001
CSDD total score	4.2 (4.2)	6.1 (4.6)	−4.03 <sup>‡</sup>	<.001
RAID total score	4.5 (4.4)	6.0 (5.6)	−2.24 <sup>‡</sup>	.03
CANE total number of needs	14.4 (2.4)	16.1 (2.8)	−5.38 <sup>‡</sup>	<.001
DEMQoL total score	105.4 (12.2)	102.6 (12.6)	2.13 <sup>‡</sup>	.03
Currently on antipsychotics	22 (14.4)	26 (21.7)	2.46	.12

\*NPI-NH G domain, apathy, score above 0.

<sup>†</sup>Two-sample *t* test with equal variances.

<sup>‡</sup>Two-sample Wilcoxon rank-sum test *z* value; CDR, FAST.

<sup>§</sup>Total score of all 12 domains of the NPI-NH.

quality of life, and the needs of the people with dementia at baseline and after the 9-month intervention period. Severity of apathy at baseline showed significant positive correlations with severity of dementia, overall neuropsychiatric symptoms, depression, agitation, and overall needs after Bonferroni corrections ( $P < .001$ ). A total of 85 participants (44.5%; 95% CI 37.5%–51.7%) had apathy after the 9-month intervention period. Mean NPI-NH apathy score at follow-up was 2.60 (95% CI 2.08–3.13). Categorical presence of apathy among the participants did not change significantly between the 2 time points (McNemar  $\chi^2 = 0.47$ ;  $df = 1$ ;  $P = .49$ ), and the numerical increase in the NPI-NH apathy scores at follow-up was not statistically significant (Wilcoxon matched-pairs signed-rank test  $z = 1.48$ ;  $P = .14$ ). However, increased apathy correlated with increased severity of dementia ( $r_s = 0.15$ ;  $P = .04$ ), and with increased needs of the people with dementia ( $r_s = 0.20$ ;  $P = .007$ ) between the 2 time points. Moreover, it showed significant negative correlation with the changes in the quality of life for the people with dementia during the study ( $r_s = -0.15$ ;  $P = .04$ ).

### Impact of Antipsychotic Review on Apathy

Antipsychotic review alone significantly increased apathy ( $\beta = 5.37$ ;  $SE = 0.91$ ;  $P < .001$ ), (Cohen's  $d = -0.97$ ). However, antipsychotic review in combination with either social interaction (Cohen's  $d = 0.49$ ) or exercise (Cohen's  $d = 0.20$ ) reduced apathy, and this reduction was statistically significant, after adjusting for the effects of age, gender, baseline dementia severity, and baseline depressive symptoms (Table 4). Further analyses including only the participants with moderately severe and severe dementia confirmed that antipsychotic review ( $\beta = 6.75$ ;  $SE = 1.31$ ;  $P < .001$ ), when delivered alone, significantly increased the severity of apathy, and that antipsychotic review in combination with either social interaction ( $\beta = -6.59$ ;  $SE = 1.58$ ;  $P < .001$ ) or exercise ( $\beta = -10.51$ ;  $SE = 1.32$ ;  $P < .001$ ) significantly reduced the severity of apathy, after adjusting for the effects of age, gender, baseline dementia severity, and baseline depressive symptoms. Moreover, analyses including only the



**Table 2**

Baseline Characteristics of Participants Who Received and Did Not Receive Antipsychotic Review, Social Interventions, and Exercise

Characteristic	AR (n = 143) n (%) / Mean (SD)	No AR (n = 130) n (%) / Mean (SD)	SI (n = 138) n (%) / Mean (SD)	No SI (n = 135) n (%) / Mean (SD)	EX (n = 136) n (%) / Mean (SD)	No EX (n = 137) n (%) / Mean (SD)
Female gender	107 (74.8)	94 (72.3)	94 (68.1)	107 (79.3)	92 (67.7)	109 (80.0)
Age, y	85.4 (6.9)	85.1 (7.0)	84.7 (7.3)	85.8 (6.4)	85.3 (6.5)	85.2 (7.3)
Ethnicity: White	129 (90.2)	114 (87.7)	118 (85.5)	125 (92.6)	118 (86.8)	125 (91.2)
Years lived in nursing homes	2.5 (2.1)	2.1 (2.1)	2.4 (2.4)	2.2 (1.8)	2.5 (2.3)	2.0 (1.9)
CDR						
Mild, 0.5–1	19 (13.3)	14 (10.8)	13 (9.4)	20 (14.8)	17 (12.5)	16 (11.7)
Moderate, 2	59 (41.3)	53 (40.8)	49 (35.5)	63 (46.7)	51 (37.5)	61 (44.5)
Severe, 3	65 (45.5)	63 (48.5)	76 (55.1)	52 (38.5)	68 (50.0)	60 (43.8)
FAST						
Mild	19 (13.3)	11 (8.5)	7 (5.1)	23 (17.0)	13 (9.6)	17 (12.4)
Moderate	8 (5.6)	8 (6.2)	7 (5.1)	9 (6.7)	6 (4.4)	10 (7.3)
Moderately severe	92 (64.3)	84 (64.6)	91 (65.9)	85 (63.0)	89 (65.4)	87 (63.5)
Severe	24 (16.8)	27 (20.8)	33 (23.9)	18 (13.3)	28 (20.6)	23 (16.8)
NPI-NH total score*	15.3 (16.3)	18.1 (17.4)	17.6 (17.2)	15.6 (16.4)	14.7 (16.5)	18.5 (17.0)
NPI-NH apathy score†	2.0 (3.2)	2.7 (3.7)	2.2 (3.4)	2.4 (3.5)	2.1 (3.3)	2.6 (3.5)
CMAI total score	47.2 (15.8)	48.9 (18.0)	49.1 (16.6)	46.9 (17.1)	47.1 (15.9)	49.0 (17.8)
CSDD total score	4.4 (4.0)	5.6 (4.8)	5.3 (4.2)	4.7 (4.7)	4.7 (4.2)	5.3 (4.7)
RAID total score	4.8 (4.4)	5.6 (5.6)	5.3 (4.8)	5.1 (5.2)	5.2 (5.0)	5.2 (5.1)
CANE total number of needs	15.0 (2.6)	15.3 (2.8)	15.6 (2.9)	14.7 (2.5)	15.3 (2.5)	15.0 (2.9)
DEMqOL total score	105.9 (9.4)	102.2 (15.0)	106.0 (11.8)	102.4 (12.9)	105.0 (12.1)	103.3 (12.8)
Currently on antipsychotics	25 (17.5)	23 (17.7)	13 (9.4)	35 (25.9)	29 (21.3)	19 (13.9)

\*Total score of all 12 domains of NPI-NH.

†NPI-NH G domain apathy scores.

participants who did not receive any antipsychotics at the baseline confirmed that antipsychotic review ( $\beta = 4.24$ ;  $SE = 1.55$ ;  $P = .006$ ), when delivered alone, significantly increased the severity of apathy, and that antipsychotic review in combination with either social interaction ( $\beta = -4.10$ ;  $SE = 1.86$ ;  $P = .03$ ) or exercise ( $\beta = -8.93$ ;  $SE = 1.97$ ;  $P < .001$ ) significantly reduced the severity of apathy, after adjusting for the effects of age, gender, baseline dementia severity, and baseline depressive symptoms.

### Apathy and Depression

Mean CSDD score of the people with dementia was 5.00 (95% CI 4.46–5.54) at baseline, and 4.59 (95% CI 3.93–5.25) after the 9-month intervention period (Wilcoxon matched-pairs signed-rank test  $z = 0.07$ ;  $P = .94$ ). Correlation between the changes in the severity of apathy and the changes in the severity of depressive symptoms during the study was not statistically significant ( $r_s = 0.08$ ;  $P = .30$ ). Changes in the severity of apathy between the 2 time points did not significantly change the severity of depressive symptoms ( $\beta = 0.10$ ;  $SE = 0.08$ ;  $P = .22$ ), after adjusting for the effects of age, gender, and baseline dementia severity of the participants.

**Table 3**

Clinical Correlates of Apathy\* Among People With Dementia Living in Nursing Homes

Clinical variable	At baseline† (n = 273)	P‡	At follow-up,§ n = 191	P‡
CDR score	0.34	<0.001	0.37	<.001
FAST score	0.26	<0.001	0.29	.002
NPI-NH total score	0.58	<0.001	0.46	<.001
CMAI total score	0.31	<0.001	0.16	1.00
CSDD total score	0.26	<0.001	0.13	1.00
RAID total score	0.13	1.00	0.03	1.00
CANE total score	0.33	<0.001	0.16	1.00
DEMqOL total score	-0.15	0.70	-0.08	1.00

\*NPI-NH G domain, apathy, scores ranging from 0 to 12.

†Total score of all 12 domains of NPI-NH.

‡P values after Bonferroni correction for multiple testing.

§Spearman correlation coefficients after 9 months follow-up.

||Spearman correlation coefficients after 9 months follow-up.

### Discussion

This study has confirmed that apathy is common in people with dementia living in nursing homes, and identified significant correlations with the severity of dementia and other neuropsychiatric

**Table 4**

Changes in the Severity of Apathy\* Following Antipsychotic Review and Non-pharmacological Interventions in People With Dementia Living in Nursing Homes

Intervention	AR Alone, n = 43	AR and SI, n = 31	AR and EX, n = 27
Baseline apathy score, mean (SD)	1.37 (2.02)	1.77 (3.27)	2.74 (3.89)
Antipsychotic use at baseline, n (%)	6 (13.95)	1 (3.23)	9 (33.33)
Follow-up apathy score, mean (SD)	4.13 (4.13)	2.28 (3.58)	1.05 (2.16)
Changes in apathy from baseline to follow-up, mean (SD)	2.75 (4.09)	0.36 (4.10)	-1.05 (4.13)
Discontinuing antipsychotics, n (%)†	5 (11.63)	0 (0.00)	2 (7.41)
Unadjusted difference in apathy between the groups, mean (SD)‡	5.58 (4.31)	3.19 (4.35)	1.78 (4.39)
Adjusted difference in apathy between the groups, β§	5.37	-5.84	-7.54
95% CI of β	3.58–7.15	-8.10 to -3.58	-9.35 to -5.72
z	5.90	-5.06	-8.14
P	<.001	<.001	<.001

\*Neuropsychiatric inventory- nursing home version (NPI-NH) G domain, apathy, scores.

†Number of people who were on antipsychotics at baseline but not on antipsychotics at the follow-up.

‡Unadjusted differences among the changes in the severity of apathy from baseline to follow-up between the intervention arm and the participants who did not receive any interventions except PCC (n = 33).

§Regression coefficients, estimated by multilevel mixed effects linear regression model with the changes in the severity of apathy as the dependent variable, nursing homes as the clustering variable, various interventions as the independent variables, and age and gender of the participants, as well as FAST and CSDD scores at baseline as covariates. Participants who did not receive any interventions except PCC formed the reference group (n = 33).

||Clustered robust SEs were calculated with nursing homes as the clustering variable.

symptoms. Worsening of apathy over 9 months of follow-up was significantly associated with increased overall needs, and with worsening quality of life. Importantly, antipsychotic review was associated with worsening apathy. However, when antipsychotic review was undertaken in combination with social interaction or personalized exercise, this not only mitigated the apparent detrimental impact but led to significant improvement. Changes in the severity of apathy were not significantly correlated with the changes in the severity of depressive symptoms, providing further evidence that apathy is an independent neuropsychiatric syndrome. Correlations of apathy with CMAI, CSDD, and RAID scores were not statistically significant after follow-up. This finding may be explained either by smaller numbers at the follow-up or by distinct progressive courses of these neuropsychiatric symptoms associated with dementia.

The detrimental impact of antipsychotic review on apathy is an important point, and consistent with detrimental effects on other neuropsychiatric symptoms.<sup>20</sup> Antipsychotic review was conducted by following guidance on managing neuropsychiatric symptoms that was published during the UK government drive to reduce antipsychotic use in the past 5 years, which has led to substantial reductions. This guidance has led to a shift in the landscape of antipsychotic prescribing in the United Kingdom whereby people now receiving antipsychotic medications have more severe neuropsychiatric symptoms than the previous cohorts. The additional evidence from this study that discontinuation of antipsychotics also affects apathy adds weight to the need for review of the existing guidelines, including greater emphasis on the use of evidence-based nonpharmacological interventions in conjunction with antipsychotic review.

Prevalence of apathy among the participants of this study was similar to the mean prevalence of apathy, reported by a recent systematic review,<sup>9</sup> in people with dementia living in nursing homes. Our findings corroborate previous studies that have reported the importance of apathy in increasing needs and worsening quality of life of people with dementia.<sup>12,19,39</sup> Categorical presence of apathy among the participants did not change significantly between the 2 time points of this study. Moreover, apathy and depressive symptoms differed on their courses and their responses to study interventions.<sup>20</sup> Such persistence, prognostic significance, and distinctness from depression argue for the nosological validity of apathy as a separate neuropsychiatric syndrome. Recognizing apathy as a separate syndrome and validating proposed diagnostic criteria for apathy<sup>40</sup> will reduce underrecognition<sup>41</sup> and should lead to improvement of its management in people with dementia.

Strengths of this study include a robust design, with a relatively large sample size and long follow-up period, the inclusion of people with moderately severe and severe dementia, and high retention of surviving participants. The interventions followed best practice guidelines for antipsychotic review and evidence-based approaches for social interaction as well as exercise, and analyses explored the effects of combined interventions. Selection bias was minimized by randomization, and by including all eligible consenting residents in the nursing homes. Observer bias was reduced by blinding the research assistants, who assessed outcomes, to intervention allocation. Contamination was avoided by the cluster RCT design. It is important to acknowledge some limitations of the study. Definition of apathy is still evolving,<sup>42</sup> and standardized assessment guidelines to diagnose apathy are lacking.<sup>6,10</sup> Reduction of apathy was not the primary outcome of the WHELD trial, and the randomization did not stratify the participants on the presence of apathy.<sup>20</sup> Moreover, our analyses considered all subtypes of dementia as 1 category, but the effects of studied interventions on apathy in people with various subtypes of dementia may differ. Furthermore, the pragmatic nature of this RCT allowed including people with multiple concurrent medications.

Weak evidence base for available nonpharmacological interventions for apathy in people with dementia may be attributed to poor quality of research rather than lack of efficacy of these interventions.<sup>10</sup> Apathy in people with dementia, including those with severe dementia living in nursing homes, can be approached with therapeutic optimism. Significant reduction in the severity of apathy can be achieved, if judicial review of pharmacological interventions is combined with appropriate nonpharmacological interventions. Standardizing assessment guidelines and diagnostic criteria for apathy is essential to evaluate the efficacy of potential interventions, and to investigate the neurobiological mechanisms underlying apathy. More large and rigorous RCTs investigating the efficacy of combined pharmacological and nonpharmacological interventions to reduce apathy in people with dementia are needed.

## Conclusion

This study confirms the high prevalence and impact of apathy in people with dementia living in nursing homes. Of particular note, review of antipsychotic medication as a single therapeutic intervention led to a significant worsening in apathy. However, undertaking antipsychotic review in conjunction with the implementation of evidence-based nonpharmacological interventions led to significant improvements. The results emphasize the importance of amending current best practice guidelines to emphasize the importance of implementing nonpharmacological interventions as part of the process of reviewing and discontinuing antipsychotic medication in people with dementia.

## Acknowledgments

APR thanks the mental health of older adults and dementia clinical academic group, South London and Maudsley NHS foundation trust (SLaM) for supporting his time for this work. CB and AC thank the NIHR Mental Health Biomedical Research Centre and Dementia Unit at South London and Maudsley NHS Foundation Trust and Institute of Psychiatry, King's College London for supporting their time for this work. NWORTH, the Bangor University clinical trials unit, oversaw randomization, data management, and quality assurance for the WHELD study.

We thank all WHELD Investigators: Martin Orrell, YongZhong Sun, Esme Moniz-Cook, Jane Stafford, Rhiannon Whitaker, Anne Corbett, Lucy Garrod, Bob Woods, Zunera Khan, Barbara Woodward-Carlton, Jennifer Wenborn, Jane Fossey, Joanna Murray, Vanessa Lawrence, Renee Romeo, Martin Knapp, Apricot Hulse, Byron Cresse, Nicola Ferreria, Michaela Litchmore Dunbar, Claire Burley, Georgina Hughes, Jasmin Patel, Azucena Guzman Garcia, and Astrid Schepers; the members of the data monitoring and ethics committee: John O'Brien (Chair), Ian James, and Clive Holmes; and the members of the program steering committee: Robin Jacoby (Chair), Dawn Brooker, Des Kelly, Geir Selbaek, and Graham Stokes.

## References

1. Corbett A, Nunez K, Thomas A. Coping with dementia in care homes. *Maturitas* 2013;76:3–4.
2. Alzheimer's Disease International. World Alzheimer's Report: Journey of caring, an analysis of long-term care in dementia; 2013. Available at: <http://www.alz.co.uk/research/WorldAlzheimerReport2013ExecutiveSummary.pdf>. Accessed September 8, 2014.
3. Corbett A, Smith J, Creese B, Ballard C. Treatment of behavioral and psychological symptoms of Alzheimer's disease. *Curr Treat Options Neurol* 2012;14: 113–125.
4. Ballard C, Corbett A. Agitation and aggression in people with Alzheimer's disease. *Curr Opin Psychiatry* 2013;26:252–259.
5. Starkstein SE, Petracca G, Chemerinski E, Kremer J. Syndromic validity of apathy in Alzheimer's disease. *Am J Psychiatry* 2001;158:872–877.

6. Robert P, Onyike CU, Leentjens AF, et al. Proposed diagnostic criteria for apathy in Alzheimer's disease and other neuropsychiatric disorders. *Eur Psychiatry* 2009;24:98–104.
7. Ishii S, Weintraub N, Mervis JR. Apathy: A common psychiatric syndrome in the elderly. *J Am Med Dir Assoc* 2009;10:381–393.
8. Starkstein SE, Jorge R, Mizrahi R, Robinson RG. A prospective longitudinal study of apathy in Alzheimer's disease. *J Neurol Neurosurg Psychiatry* 2006;77:8–11.
9. Selbaek G, Engedal K, Bergh S. The prevalence and course of neuropsychiatric symptoms in nursing home patients with dementia: A systematic review. *J Am Med Dir Assoc* 2013;14:161–169.
10. Brodaty H, Burns K. Nonpharmacological management of apathy in dementia: A systematic review. *Am J Geriatr Psychiatry* 2012;20:549–564.
11. Vilalta-Franch J, Calvo-Perxas L, Garre-Olmo J, et al. Apathy syndrome in Alzheimer's disease epidemiology: Prevalence, incidence, persistence, and risk and mortality factors. *J Alzheimers Dis* 2013;33:535–543.
12. Holtta EH, Laakkonen ML, Laurila JV, et al. Apathy: Prevalence, associated factors, and prognostic value among frail, older inpatients. *J Am Med Dir Assoc* 2012;13:541–545.
13. Volicer L, Frijters DH, van der Steen JT. Apathy and weight loss in nursing home residents: Longitudinal study. *J Am Med Dir Assoc* 2013;14:417–420.
14. Berman K, Brodaty H, Withall A, Seeher K. Pharmacologic treatment of apathy in dementia. *Am J Geriatr Psychiatry* 2012;20:104–122.
15. Rea R, Carotenuto A, Fasanaro AM, et al. Apathy in Alzheimer's disease: Any effective treatment? *ScientificWorldJournal* 2014;2014:421385.
16. van Reekum R, Clarke D, Conn D, et al. A randomized, placebo-controlled trial of the discontinuation of long-term antipsychotics in dementia. *Int Psychogeriatr* 2002;14:197–210.
17. Buettner LL, Fitzsimmons S, Atav S, Sink K. Cognitive stimulation for apathy in probable early-stage Alzheimer's. *J Aging Res* 2011;2011:480890.
18. Telenius EW, Engedal K, Bergland A. Effect of a high-intensity exercise program on physical function and mental health in nursing home residents with dementia: An assessor blinded randomized controlled trial. *PLoS One* 2015;10:e0126102.
19. Politis AM, Vozzella S, Mayer LS, et al. A randomized, controlled, clinical trial of activity therapy for apathy in patients with dementia residing in long-term care. *Int J Geriatr Psychiatry* 2004;19:1087–1094.
20. Ballard C, Orrell M, YongZhong S, et al. Impact of antipsychotic review and nonpharmacological intervention on antipsychotic use, neuropsychiatric symptoms, and mortality in people with dementia living in nursing homes: A factorial cluster-randomized controlled trial by the Well-Being and Health for People With Dementia (WHELD) Program. *Am J Psychiatry* 2016;173:252–262.
21. Whitaker R, Fossey J, Ballard C, et al. Improving Well-being and Health for People with Dementia (WHELD): study protocol for a randomised controlled trial. *Trials* 2014;15:284.
22. Morris JC. The Clinical Dementia Rating (CDR): Current version and scoring rules. *Neurology* 1993;43:2412–2414.
23. Reisberg B. Functional Assessment Staging (FAST). *Psychopharmacol Bull* 1984;1988:653–659.
24. Fossey J, Ballard C, Juszcak E, et al. Effect of enhanced psychosocial care on antipsychotic use in nursing home residents with severe dementia: Cluster randomised trial. *BMJ* 2006;332:756–761.
25. Fossey J, Masson S, Stafford J, et al. The disconnect between evidence and practice: A systematic review of person-centred interventions and training manuals for care home staff working with people with dementia. *Int J Geriatr Psychiatry* 2014;29:797–807.
26. National Institute for Health and Clinical Excellence (NICE). Dementia: Supporting people with dementia and their carers in health and social care; 2006. Available at: <https://www.nice.org.uk/guidance/cg42>. Accessed June 16, 2014.
27. Alzheimer's Society. Optimising treatment and care for behavioural and psychological symptoms of dementia: A best practice guide; 2012. Available at: [http://southwestyorkshire.nhs.uk/wp-content/uploads/2012/06/A\\_best\\_practice\\_guide\\_for\\_health\\_and\\_social\\_care\\_professionals.pdf](http://southwestyorkshire.nhs.uk/wp-content/uploads/2012/06/A_best_practice_guide_for_health_and_social_care_professionals.pdf). Accessed April 23, 2014.
28. Ballard CG, Thomas A, Fossey J, et al. A 3-month, randomized, placebo-controlled, neuroleptic discontinuation study in 100 people with dementia: The neuropsychiatric inventory median cutoff is a predictor of clinical outcome. *J Clin Psychiatry* 2004;65:114–119.
29. Teri L, Logsdon RG, McCurry SM. Exercise interventions for dementia and cognitive impairment: The Seattle Protocols. *J Nutr Health Aging* 2008;12:391–394.
30. Buettner L, Fitzsimmons S. N.E.S.T Approach: Dementia Practice Guidelines for Disturbing Behaviours. State College, PA: Venture Publishing, Inc; 2009.
31. Cohen-Mansfield J, Thein K, Marx MS, et al. Efficacy of nonpharmacologic interventions for agitation in advanced dementia: A randomized, placebo-controlled trial. *J Clin Psychiatry* 2012;73:1255–1261.
32. Russell D, Hoare ZS, Whitaker R, et al. Generalized method for adaptive randomization in clinical trials. *Stat Med* 2011;30:922–934.
33. Cummings JL, Mega M, Gray K, et al. The Neuropsychiatric Inventory: Comprehensive assessment of psychopathology in dementia. *Neurology* 1994;44:2308–2314.
34. Alexopoulos GS, Abrams RC, Young RC, Shamoian CA. Cornell Scale for Depression in Dementia. *Biol Psychiatry* 1988;23:271–284.
35. Snow AL, Huddleston C, Robinson C, et al. Psychometric properties of a structured interview guide for the rating for anxiety in dementia. *Aging Ment Health* 2012;16:592–602.
36. Cohen-Mansfield J, Marx MS, Rosenthal AS. A description of agitation in a nursing home. *J Gerontol* 1989;44:M77–M84.
37. Reynolds T, Thornicroft G, Abas M, et al. Camberwell Assessment of Need for the Elderly (CANE). Development, validity and reliability. *Br J Psychiatry* 2000;176:444–452.
38. Smith SC, Lamping DL, Banerjee S, et al. Development of a new measure of health-related quality of life for people with dementia: DEMQOL. *Psychol Med* 2007;37:737–746.
39. Yeager CA, Hyer L. Apathy in dementia: Relations with depression, functional competence, and quality of life. *Psychol Rep* 2008;102:718–722.
40. Mulin E, Leone E, Dujardin K, et al. Diagnostic criteria for apathy in clinical practice. *Int J Geriatr Psychiatry* 2011;26:158–165.
41. Cipriani G, Lucetti C, Danti S, Nuti A. Apathy and dementia. Nosology, assessment and management. *J Nerv Ment Dis* 2014;202:718–724.
42. Clarke DE, Ko JY, Kuhl EA, et al. Are the available apathy measures reliable and valid? A review of the psychometric evidence. *J Psychosom Res* 2011;70:73–97.